Rong Qi, Ph.D., Professor, doctoral advisor, and deputy director of the Department of Pharmacology at the Peking University School of Basic Medicine. She is engaged in research on intervention and drug development for metabolic cardiovascular diseases. Her work focuses on identifying clinically translatable active compounds from both natural and chemically synthesized small molecules targeting newly discovered and known targets of cardiovascular diseases. She also designs in vivo delivery systems tailored to different administration routes based on the physicochemical properties of these compounds to enhance drug bioavailability and therapeutic efficacy. Her research has led to the discovery of the reparative effect of cycloastragenol from the traditional Chinese medicine Astragalus on aortic aneurysm vascular injury; the intervention of naringin from citrus fruits on metabolic dysfunction-associated steatohepatitis (MASH); and the inhibitory effects of medicinal fungi Antrodia Cinnamomea and Inonotus Obliquus on cardiac and vascular remodeling diseases. In the past five years, she has published over 30 papers as the corresponding author in journals such as Biomaterials (2024), J Adv Sci (2024), Adv Healthc Mater (2024), Mol Pharm (2023), and Br J Pharmacol (2020). She has led research projects funded by the National Natural Science Foundation of China, the National Key Research and Development Program of the Ministry of Science and Technology, and the Beijing Natural Science Foundation, etc. She holds 7 authorized drug invention patents.